To verify that the transplanted CD8+ T cells were responsible for this glioma-protective capacity, we challenged these SCID survivors with glioma cells combined with αCD8, αCD4, or αAsialo-GM1 antibodies to deplete CD8+ T cells, CD4+ T cells, and natural killer (NK) cells, respectively. The gene discussed is CD4; the disease is central nervous system cancer.